President’s foreword for RNIB Report ‘Real Patients Coming to Real Harm’ Wales
A substantial part of the workload of ophthalmology services is the care of long term conditions such as glaucoma, diabetic retinopathy and age-related macular degeneration. These conditions all become increasingly common with advancing age and all require timely recognition and treatment in order to avoid preventable sight loss. Unfortunately, clinical services for these long-term conditions
French health regulator reviews use of Avastin to treat AMD
College Statement The RCOphth notes with interest the move by the French health regulator, French National Agency for Medicines and Health Products Safety (ANSM), in asking Roche to provide information on the safety and efficiency of the off-label use of bevacizumab (Avastin) to treat wet age-related macular degeneration (AMD). Ranibizumab (Lucentis), which is licensed as
RCOphth secures National Ophthalmology Database (NOD) Audit Project contract
The Royal College of Ophthalmologists (RCOphth) is delighted to announce that we have been awarded a contract to manage the National Ophthalmology Audit Programme (RCOphth NOA). The RCOphth will deliver this vital initiative which is commissioned by the Healthcare Quality Improvement Partnership as part of the National Clinical Audit Programme. Building on the achievements of
RCOphth recommends appraisal of the use of bevacizumab (Avastin) for age related macular degeneration
The Royal College of Ophthalmologists recommends UK regulatory bodies appraise the use of bevacizumab (Avastin) for age related macular degeneration potentially saving the NHS over £100million a year Age related macular degeneration (AMD) is the commonest cause of blindness among elderly people in the developed world1. The ageing population in the UK and associated eye
RCOphth invited to address All Party Parliamentary Group
‘Upskilled non-medically qualified professionals are needed as part of an ophthalmology led service to support an increase in capacity’ Miss Melanie Corbett, Consultant Ophthalmologist at Western Eye Hospital, Imperial College NHS Trust, London and Executive Committee Member of the RCOphth, spoke at a meeting of the All Party Parliamentary Group for Eye Health and Visual